Teramet Tablet 50/500 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
MFDS item code 201505936 · Approved 2015.08.25
This product's status changed to Expired on 2025.08.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medicine helps improve blood sugar control when taken together with sitagliptin and metformin in patients with type 2 diabetes. It is more effective when used in conjunction with dietary management and exercise therapy, aiding in blood sugar management and improving diabetes treatment.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment due to its metformin component (see Precautions for Use, 2. Do not administer to the following patients).
This medicine is a combination drug containing sitagliptin and metformin hydrochloride, primarily used for the treatment of type 2 diabetes. When taking this medicine, severe hypersensitivity reactions may occur. If there are symptoms such as rash, hives, or difficulty breathing, stop taking it immediately and consult a doctor. Acute pancreatitis has been rarely reported, so if symptoms such as abdominal pain, nausea, or vomiting occur after taking the medicine, inform a healthcare professional promptly. Metformin hydrochloride contained in this medicine can rarely cause a severe side effect known as lactic acidosis; therefore, patients with impaired kidney function or liver diseases should take special care. Patients with severe renal impairment, acute infection, heart failure, or pregnant or breastfeeding women should not take this medicine. It should also be temporarily discontinued before and after examinations using radiopaque iodine contrast agents. Patients with irregular eating habits or engaging in vigorous exercise, as well as those taking other medications, should be cautious as there is a risk of hypoglycemia or lactic acidosis. While taking this medicine, it is important to regularly check kidney function, blood tests, and vitamin B12 levels. Alcohol consumption may increase the risk of lactic acidosis, so excessive drinking should be avoided during treatment. If surgery is planned, this medicine should be discontinued 48 hours prior to the surgery and resumed only after confirming that kidney function has returned to normal post-operatively. Hypoglycemic symptoms may appear; thus, especially patients taking insulin or other hypoglycemic agents should closely monitor symptoms and consult a doctor if necessary. The safety and efficacy of this medicine in children under 18 years of age have not been established, so it is not recommended for pediatric use. Elderly patients may have decreased kidney function, thus dose adjustments and regular monitoring of kidney function are necessary. In case of overdose, seek medical attention immediately for appropriate treatment, as this medicine can be partially removed by hemodialysis. Possible adverse reactions during the course of treatment include diarrhea, nausea, headache, upper respiratory infection, etc. If severe joint pain or skin rash occurs, promptly inform a physician.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly sealed container to prevent air or moisture from entering and is best kept at room temperature between 1°C and 30°C. Storing in this manner helps maintain the efficacy of the drug.
Pink oval film-coated tablets
In-house packaging unit
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.